All In Biotech

Drug Trial Radar · NCT04499248

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

100

Actual

Start

Nov 16, 2020

Primary completion

Apr 2029

Study completion Apr 2029

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension

Conditions

  • Open-angle Glaucoma
  • Ocular Hypertension

Interventions

  • AGN-193408 SRDrug

    An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.

  • LumiganOther

    Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost

  • Sham AdministrationOther

    Needleless applicator contacting similar intracameral insertion location on eye as AGN-193408 SR.

  • Lumigan VehicleOther

    Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 2.

  • AGN-193408 SRDrug

    An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.

  • Sham AdministrationOther

    Needleless applicator contacting similar insertion location on eye as AGN-193408 SR.

  • Lumigan VehicleOther

    Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Hour 0 Intraocular Pressure (IOP) in the Study EyeTime frame: Baseline to Month 36
  2. Number of participants experiencing treatment emergent adverse eventsTime frame: Baseline to Month 36

Locations

49 sites in 2 countries. Site status is shown where the registry gives one.

  • Horizon Eye Specialists & Lasik Center - Sun City /ID# 252153

    Sun City, Arizona

  • Global Research Management /ID# 241699

    Glendale, California

  • United Medical Research Institute /ID# 241701

    Inglewood, California

  • Lakeside Vision Center /ID# 241698

    Irvine, California

  • The Eye Research Foundation /ID# 234528

    Newport Beach, California

  • Sacramento Eye Consultants /ID# 241697

    Sacramento, California

  • Premiere Practice Management LLC /ID# 235957

    Torrance, California

  • Wolstan & Goldberg Eye Associates /ID# 241700

    Torrance, California

  • Connecticut Eye Consultants P.C. /ID# 235862

    Danbury, Connecticut

  • Brandon Eye Associates - Brandon /ID# 276600

    Brandon, Florida

  • Nature Coast Clinical Research - Crystal River /ID# 237781

    Crystal River, Florida

  • Advanced Research, LLC /ID# 276987

    Deerfield Beach, Florida

  • University of Florida Health Ophthalmology - Jacksonville /ID# 243122

    Jacksonville, Florida

  • East Florida Eye Institute /ID# 235762

    Stuart, Florida

  • Logan Ophthalmic Research Inc. /ID# 252087

    Tamarac, Florida

  • Coastal Research Associates /ID# 234649

    Roswell, Georgia

  • Thomas Eye Group PC /ID# 266775

    Sandy Springs, Georgia

  • University of Illinois Hospital and Health Sciences System /ID# 253630

    Chicago, Illinois

  • Midwest Medical Advisors Inc /ID# 235845

    Carmel, Indiana

  • Indiana University - Glick Eye Institute /ID# 235887

    Indianapolis, Indiana

  • Ophthalmic Consultants of Boston /ID# 236535

    Boston, Massachusetts

  • Fraser Eye Care Center /ID# 267100

    Fraser, Michigan

  • Midwest Vision Research Foundation at Pepose Vision Institute /ID# 267094

    Chesterfield, Missouri

  • Silverstein Eye Centers /ID# 266767

    Kansas City, Missouri

  • Tekwani Vision Center /ID# 235149

    St Louis, Missouri

  • Nv Eye Surgery - Henderson /ID# 276925

    Henderson, Nevada

  • Rutgers New Jersey Medical School Campus, Doctors Office Center /ID# 234365

    Newark, New Jersey

  • Northern New Jersey Eye Institute /ID# 241545

    South Orange, New Jersey

  • Asheville Eye Associates /ID# 234963

    Asheville, North Carolina

  • Private Practice - Dr. James D. Branch /ID# 234560

    Winston-Salem, North Carolina

  • The Ohio State University /ID# 267590

    Columbus, Ohio

  • Oklahoma Eye Surgeons /ID# 252089

    Oklahoma City, Oklahoma

  • Drs Fine Hoffman & Sims LLC /ID# 235919

    Eugene, Oregon

  • Scott and Christie and Associates /ID# 252284

    Cranberry Township, Pennsylvania

  • Eye Specialty Group /ID# 252201

    Memphis, Tennessee

  • Vanderbilt Eye Institute /ID# 266915

    Nashville, Tennessee

  • Advancing Vision Research /ID# 236683

    Smyrna, Tennessee

  • Macro Trials (SMO/Network/Consortium) /ID# 266772

    Austin, Texas

  • San Antonio Eye Center /ID# 272087

    San Antonio, Texas

  • St. George Eye Center /ID# 236200

    St. George, Utah

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.